Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 29Other solid neoplasm 10Sarcoma 7Gynecologic 6Gastrointestinal 4Breast 4Tumor-Agnostic 3NET 3Endocrine 3Other hematologic neoplasm 1Genitourinary 1CNS 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × PM 01183 × Tumor-Agnostic × Clear all
NCT05126433 2025-02-28

JAZZ EMERGE201

Jazz Pharmaceuticals

Phase 2 Terminated
47 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01980667 2017-01-26

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

PharmaMar

Phase 1 Completed
41 enrolled
Tumor-Agnostic

Neoplasms

NCT01970553 2015-04-01

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
47 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡